TREACE MEDICAL CONCEPTS, INC.

Treace Medical Concepts reported its third quarter 2026 financial results, with revenue at $48.3 million, a 4% decrease year-over-year. The company improved its net loss by 23% to $(12.6) million and its Adjusted EBITDA by $2.9 million to $0.3 million compared to the prior year period. Year-to-date cash usage was reduced by 53%. Treace updated its full-year 2026 revenue guidance to $206-$210 million and improved its Adjusted EBITDA guidance to a loss of $1.0-$2.0 million.

Treace Medical Concepts reported Q2 2026 financial results with revenue of $45.4 million, a 4% decrease year-over-year, but an improved net loss of $(15.9) million and adjusted EBITDA of $(3.5) million. The company significantly reduced year-to-date cash usage by 57% and ended the quarter with $45.6 million in cash and equivalents. Treace also raised its full-year 2026 revenue guidance to a range of $204 million to $212 million and narrowed its Adjusted EBITDA loss expectation to $3.0 million to $5.0 million, driven by increasing surgeon adoption of its expanded bunion portfolio and new product launches.

Treace Medical Concepts, Inc. reported Q2 2026 revenue of $45.4 million, a 4% decrease year-over-year, and a net loss of $(15.9) million, an improvement from the prior year. The company also reported an improved Adjusted EBITDA of $(3.5) million and a 57% reduction in year-to-date cash usage. Following these results, Treace Medical raised its full-year 2026 revenue guidance to a range of $204 million to $212 million and updated its Adjusted EBITDA loss guidance to $3.0 million to $5.0 million. Operational highlights include the limited market release of SuperBite™ and increased adoption of its expanded bunion portfolio.

Treace Medical Concepts, Inc. announced it will release its financial results for the second quarter of 2026 before market open on Friday, August 7, 2026. Following the release, company management will host a conference call at 8:00 am ET to discuss the results. Investors can register to participate in the call, and a webcast will be available on the company's investor relations website.

Treace Medical Concepts, Inc. announced the successful completion of the first surgical case using its new HyperPlate XM Dynamic Compression Locking Implant. This advanced fixation technology, an extension of the SpeedPlate platform, is designed for midfoot and hindfoot procedures, offering dynamic compression and enhanced stability. The system also includes new GreatReleaseXM Rapid Release Instruments for efficient joint preparation. Full commercialization of the HyperPlate XM system is expected in the third quarter of 2026, expanding Treace's market reach in foot and ankle solutions.

Treace Medical Concepts, Inc. announced its participation in the Sidoti Small Cap Conference, scheduled for Thursday, June 18, 2026, at approximately 1:45 pm ET. Investors can access a live webcast and replay of the presentation via the company's investor relations website. Treace Medical is a medical technology company focused on advancing surgical treatments for bunions and midfoot deformities with systems like Lapiplasty and Adductoplasty.

Treace Medical Concepts, Inc. held its 2026 Annual Meeting of Stockholders on May 19, 2026. Stockholders elected three Class II directors to serve three-year terms. Additionally, they approved, on an advisory basis, the compensation of the company's named executive officers and ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Treace Medical Concepts reported a significant decline in Q1 2026 revenue, falling 10.2% to $47.198 million, and a wider net loss of $17.961 million compared to the prior year. Despite a decrease in total operating expenses and an increase in net cash provided by operating activities, the company's core financial performance deteriorated. The company also adjusted the useful life of its surgical instruments, which reduced depreciation expense by $1.2 million for the quarter, and secured a new $125 million term loan facility, drawing $60 million.

Treace Medical Concepts reported its first quarter 2026 financial results, with revenue decreasing 10% year-over-year to $47.2 million and net loss widening to $(18.0) million. Adjusted EBITDA also saw a larger loss of $(5.5) million. Despite the financial declines, the company increased its cash, cash equivalents, and marketable securities to $51.9 million and initiated the limited market release of its SuperBite Compression Screw System. Treace Medical reaffirmed its full-year 2026 revenue guidance and expects a reduction in cash usage by approximately 50% for the full year, anticipating stronger growth in the second half.

Treace Medical Concepts, Inc. announced it will release its first quarter 2026 financial results before the market opens on Friday, May 8, 2026. Following the release, company management will host a conference call at 8:00 am ET to discuss the results. Investors can register to participate in the call or access a live and archived webcast on the company's investor relations website.